Moderna, Inc. (NASDAQ: MRNA) saw its stock soar 5.33% in pre-market trading on Monday, as investors reacted positively to the company's announcement of its upcoming presentations at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress.
The biotechnology company revealed that it will present research across multiple infectious disease areas, including COVID-19, influenza, respiratory syncytial virus (RSV), cytomegalovirus (CMV), norovirus, and mpox, at the prestigious conference in Vienna, Austria, from April 11-15, 2025. Moderna's strong presence at the event, with twelve scientific presentations including three oral presentations, demonstrates the breadth and depth of its research pipeline in respiratory and emerging infectious diseases.
The market's enthusiastic response to this news highlights the continued importance of Moderna's mRNA technology platform and its potential applications beyond COVID-19 vaccines. As the company strives to expand its portfolio and showcase its capabilities in addressing various infectious diseases, investors appear to be betting on Moderna's long-term growth prospects and its ability to maintain its position as a leader in mRNA-based medicines.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。